Prescient Medicine Holdings LLC and Metabiomics Corp. have announced a joint venture to develop a microbiome diagnostics platform for detecting precancerous colon polyps and diagnosing other types of gastrointestinal diseases, according to a company press release.

“These simple yet incredibly powerful tools will dramatically change the equation when it comes to earlier identification of precancerous conditions, leading to early treatment decisions, reduced costs and better outcomes,” Keri Donaldson, founder and CEO of Prescient Medicine, said in the release.